SCHEMBL17429552

SCHEMBL17429552

Clc1ccc2c(c1)O[C@@H](c1ccccc1)n1c-2cc2cc(Cl)ccc21

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ACLY P53396 9/20 0.34
CYP19A1 P11511 1/20 0.33
EGFR P00533 1/20 0.32
CCR2 P41597 1/20 0.30
CYP2A6 P11509 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17429734 1.00 ACLY (0.34) ACLYCYP19A1EGFRCCR2CYP2A6
SCHEMBL903682 0.92 ACLY (0.34) ACLYCYP19A1
SCHEMBL17429553 0.92 ACLY (0.34) ACLYCYP19A1
SCHEMBL18957720 0.92 MAOB (0.40) ACLYCYP19A1
SCHEMBL18957722 0.92 MAOB (0.40) ACLYCYP19A1
SCHEMBL903686 0.92 ACLY (0.31) ACLYCYP19A1
SCHEMBL903685 0.92 ACLY (0.34) ACLYCYP19A1
SCHEMBL903687 0.92 ACLY (0.31) ACLYCYP19A1
SCHEMBL17429555 0.82 CYP19A1 (0.33) CYP19A1CYP2A6
SCHEMBL19318923 0.80 PIK3CA (0.31) ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10457690-B2 Process for preparing substituted tetracyclic heterocycle compounds MERCK SHARP & DOHME CORP. (US) 2019-10-29 US disclosed
US-10202401-B2 Process for making tetracyclic heterocycle compounds MSD R&D CN CO., LTD (CN) 2019-02-12 US disclosed
US-20180179223-A1 PROCESS FOR PREPARING SUBSTITUTED TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
US-20180179223-A1 PROCESS FOR PREPARING SUBSTITUTED TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
US-20180065985-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARPE & DOHME CORP. (US) 2018-03-08 US disclosed
US-20180065985-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARPE & DOHME CORP. (US) 2018-03-08 US disclosed
US-20170166586-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MSD R&D (CHINA) CO., LTD (CN) 2017-06-15 US disclosed
US-20170166586-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MSD R&D (CHINA) CO., LTD (CN) 2017-06-15 US disclosed
WO-2016196932-A1 PROCESS FOR PREPARING SUBSTITUTED TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2016-12-08 WO disclosed
WO-2016004899-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2016-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10457690-B2 Process for preparing substituted tetracyclic heterocycle compounds ABL1, GTF3C5, TPI1 ACLY 1201/4885CYP19A1 350/4885EGFR 1911/4885
US-10202401-B2 Process for making tetracyclic heterocycle compounds CYP1B1, CYP1A2, CYP2F1 ACLY 1087/4885CYP19A1 54/4885EGFR 1508/4885
US-20180179223-A1 PROCESS FOR PREPARING SUBSTITUTED TETRACYCLIC HETEROCYCLE COMPOUNDS ABL1, GTF3C5, TPI1 ACLY 1201/4885CYP19A1 350/4885EGFR 1911/4885
US-20170166586-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS CYP1A2, CYP3A5, CYP1B1 ACLY 1184/4885CYP19A1 48/4885EGFR 1342/4885
US-20180065985-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS CYP1B1, CYP1A2, CYP2F1 ACLY 1087/4885CYP19A1 54/4885EGFR 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.